Premium
Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon‐α in interferon nonresponders with chronic hepatitis C
Author(s) -
Ferenci P.,
Stauber R.,
SteindlMunda P.,
Gschwantler M.,
Fickert P.,
Datz C.,
Müller C.,
Hackl F.,
Rainer W.,
WatkinsRiedel T.,
Lin W.
Publication year - 1999
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1046/j.1365-2893.1999.00005.x
Subject(s) - ribavirin , gastroenterology , medicine , cirrhosis , interferon , randomized controlled trial , alpha interferon , interim analysis , liter , group b , chronic hepatitis , group a , immunology , virus
This trial investigated the efficacy of a combination of high‐dose interferon‐α (IFN‐α) with ribavirin in IFN nonresponders. Study protocol: 304 patients with chronic hepatitis C were treated with 5 MU IFN‐α2b (IntronA ® , Schering‐Plough) per TIW for 3 months. Nonresponders (defined by HCV‐RNA positivity in serum after the 3 months of therapy) were randomized either to continue with IFN (5 MU IFN per TIW followed by 10 MU per TIW for each 3 months) alone (group A) or in combination with ribavirin (1–1.2 g per day) (group B). ALT was measured in monthly intervals, HCV‐RNA in 3 monthly intervals. Pretreatment characteristics of the randomized patients were as follows: group A, n = 76; m/f, 54/22; 16% cirrhosis, age, 45.7 ± 12 years; ALT (U per litre), 66 ± 35; group B, n = 81; m/f, 57/24; 17% cirrhosis, age, 48.2 ± 12; ALT, 71 ± 40. After 9 months of treatment, nine (11.6%) and 27 (32.5%, P = 0.0066) patients were HCV‐RNA negative and 51 and 39 were HCV‐RNA positive, in groups A and B, respectively. There were 17 drop‐outs in group A and 15 in group B. Six months after treatment only two patients in group A (2.5%) and five (6%, P = 0.06) in group B had normal ALT and no detectable HCV‐RNA in serum. In addition to the well‐known side‐effects of IFN the mean haemoglobin concentration dropped by 2 g per litre in group B. These data indicate that a combination of high‐dose IFN with ribavirin is effective in inducing a short‐lasting complete response in one‐third of IFN nonresponders. Prolonged treatment with IFN/ribavirin may be necessary to obtain a sustained response.